Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the approval of a clinical trial by China’s National Medical Products Administration for a subsidiary’s drug combination aimed at treating advanced solid tumors. The trial will test the efficacy of FH-2001 capsule in conjunction with Serplulimab injection, marking a significant step in the company’s development of novel cancer therapies. The initiation of the Phase Ib/II clinical trial in China is anticipated once requisite conditions are met.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
